2023 World Conference on Lung Cancer (Posters)-P2.04. AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) + Durvalumab + Carboplatin as 1L Treatment of Advanced/mNSCLC

P2.04. AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) + Durvalumab + Carboplatin as 1L Treatment of Advanced/mNSCLC - PDF(Abstract)

Back to course

Pdf Summary

The AVANZAR study is a Phase III clinical trial that aims to evaluate the efficacy and safety of a combination treatment for advanced metastatic non-small cell lung cancer (mNSCLC). The study focuses on a novel antibody-drug conjugate (ADC) called Datopotamab Deruxtecan (Dato-DXd) that targets the trophoblast cell surface antigen 2 (TROP2), a protein found on the surface of many cancer cells. The ADC consists of a topoisomerase I inhibitor attached to a monoclonal antibody directed against TROP2. <br /><br />The study will compare the effectiveness of Dato-DXd in combination with durvalumab and carboplatin to standard histology-specific therapy with pembrolizumab, pemetrexed, and carboplatin or cisplatin in patients with locally advanced/mNSCLC without actionable genomic alterations. Patients participating in the study will be randomized into two treatment groups and will receive the assigned therapy for up to 35 cycles or 2 years. The primary endpoints of the study are progression-free survival (PFS) and overall survival (OS) in the TROP2-positive population. Secondary endpoints include PFS and OS in the intention-to-treat (ITT) and TROP2-negative populations, objective response rate (ORR), duration of response (DoR), and time to second progression or death (PFS2) in the ITT and TROP2-positive populations. The study will also evaluate pharmacokinetics, immunogenicity, and safety of the treatment.<br /><br />The AVANZAR study plans to enroll 1000 patients across multiple sites worldwide. The study has not yet completed enrollment, and it is classified as a clinical trial in progress. The aim of this study is to assess whether the combination of Dato-DXd, durvalumab, and carboplatin can improve outcomes for patients with advanced/mNSCLC compared to standard therapy.

Asset Subtitle

Terufumi Kato

Meta Tag

Speaker Terufumi Kato

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

AVANZAR study

Phase III clinical trial

metastatic non-small cell lung cancer

mNSCLC

antibody-drug conjugate

Datopotamab Deruxtecan

TROP2

topoisomerase I inhibitor

durvalumab

carboplatin